Literature DB >> 28341039

Cognitive impairment and BDNF serum levels.

Joanna Siuda1, Maja Patalong-Ogiewa2, Weronika Żmuda2, Magdalena Targosz-Gajniak2, Ewa Niewiadomska3, Iwona Matuszek4, Halina Jędrzejowska-Szypułka4, Joanna Lewin-Kowalik, Monika Rudzińska-Bar5.   

Abstract

BACKGROUND/AIMS: To investigate the alterations of brain-derived neurotrophic factor (BNDF) serum levels in subjects with different intensity of cognitive impairment and different neurodegenerative processes.
MATERIAL AND METHODS: Serum BDNF levels were analyzed by ELISA kit in 378 subjects: 134 Alzheimer's disease (AD) patients, 115 amnestic mild cognitive impairment (MCI) patients, and 129 controls divided into two groups: neurodegenerative control group (ND), consisting of 49 Parkinson's disease patients without any cognitive complaints, and cognitively normal control group (CN), consisting of 80 subjects without any neurological disorders.
RESULTS: AD patients had significantly lower (p<0.001) BDNF serum levels compared to MCI, CN and ND controls. Age and education had significant influence on BDNF serum levels regardless the diagnosis or group assignment. We have found no influence of depression on BDNF serum levels either in our group as a whole, or in each group assessed separately. We found significant correlation between BDNF serum levels and cognitive impairments. After multiple comparisons between the groups, we found that, after adjustment for confounding factors (age, gender, education, depression, cognitive impairment), BDNF serum levels were the lowest in AD group (p=0.05).
CONCLUSIONS: Advanced age and low educational level are associated with decreased BDNF serum levels. Decreased BDNF serum levels correspond to the severity of cognitive impairment. There is no correlation between BDNF serum levels and depressive symptoms.
Copyright © 2016. Published by Elsevier Urban & Partner Sp. z o.o.

Entities:  

Keywords:  Alzheimer's disease; Brain-derived neurotrophic factor; Cognitive impairment; Dementia; Serum brain-derived neurotrophic factor level

Mesh:

Substances:

Year:  2016        PMID: 28341039     DOI: 10.1016/j.pjnns.2016.10.001

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  24 in total

1.  Delirium and Alzheimer disease: A proposed model for shared pathophysiology.

Authors:  Tamara G Fong; Sarinnapha M Vasunilashorn; Towia Libermann; Edward R Marcantonio; Sharon K Inouye
Journal:  Int J Geriatr Psychiatry       Date:  2019-03-15       Impact factor: 3.485

2.  Andrographolide enhances hippocampal BDNF signaling and suppresses neuronal apoptosis, astroglial activation, neuroinflammation, and spatial memory deficits in a rat model of chronic cerebral hypoperfusion.

Authors:  Da-Peng Wang; Hang Yin; Qi Lin; Shu-Ping Fang; Jian-Hua Shen; Yi-Fang Wu; Shao-Hua Su; Jian Hai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-06-11       Impact factor: 3.000

3.  lncRNA MIR155HG Alleviates Depression-Like Behaviors in Mice by Regulating the miR-155/BDNF Axis.

Authors:  Zhang Huan; Zhu Mei; Huang Na; Ma Xinxin; Wang Yaping; Liu Ling; Wang Lei; Zhang Kejin; Liu Yanan
Journal:  Neurochem Res       Date:  2021-01-29       Impact factor: 3.996

Review 4.  The neuroprotective effects of oxygen therapy in Alzheimer's disease: a narrative review.

Authors:  Cui Yang; Qiu Yang; Yang Xiang; Xian-Rong Zeng; Jun Xiao; Wei-Dong Le
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

5.  Long-term high-intensity interval training increases serum neurotrophic factors in elderly overweight and obese Chinese adults.

Authors:  Xi Li; Tianyu Han; Xu Zou; Han Zhang; Wenpin Feng; Han Wang; Yulin Shen; Li Zhang; Guoliang Fang
Journal:  Eur J Appl Physiol       Date:  2021-06-20       Impact factor: 3.078

6.  Isoflurane exposure regulates the cell viability and BDNF expression of astrocytes via upregulation of TREK‑1.

Authors:  Cui-Hong Zhou; Ya-Hong Zhang; Fen Xue; Shan-Shan Xue; Yun-Chun Chen; Ting Gu; Zheng-Wu Peng; Hua-Ning Wang
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

7.  Yizhi Qingxin Formula Extract Ameliorates Cognitive Decline in Aged Rats via the Brain-Derived Neurotrophic Factor/Tropomyosin Receptor Kinase B Pathway.

Authors:  Lina Ma; Yu Cao; Feixue Wang; Zehui Li; Zhiyong Wang; Yang Yang; Hui Pei; Hao Li
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

8.  Prospective cohort study reveals MMP-9, a neuroplasticity regulator, as a prediction marker of cochlear implantation outcome in prelingual deafness treatment.

Authors:  Monika Matusiak; Dominika Oziębło; Monika Ołdak; Emilia Rejmak; Leszek Kaczmarek; Piotr Henryk Skarżyński; Henryk Skarżyński
Journal:  Mol Neurobiol       Date:  2022-01-21       Impact factor: 5.682

Review 9.  Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?

Authors:  Luisa Benussi; Giuliano Binetti; Roberta Ghidoni
Journal:  Front Neurosci       Date:  2017-12-01       Impact factor: 4.677

10.  HDACi protects against vascular cognitive impairment from CCH injury via induction of BDNF-related AMPA receptor activation.

Authors:  Yao-Ching Fang; Jia-Yu Hsieh; Amelia Nur Vidyanti; Chih-Hao Yang; Jing-Shiun Jan; Kang-Wei Chang; Chaur-Jong Hu; Yong-Kwang Tu
Journal:  J Cell Mol Med       Date:  2021-07-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.